Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

NEW ORLEANS, LA—Complete revascularization in patients presenting with ACS and multivessel coronary artery disease ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...